Gan & Lee Pharmaceuticals

Gan & Lee Pharmaceuticals company information, Employees & Contact Information

Explore related pages

Gan & Lee Pharmaceuticals email format Gan & Lee Pharmaceuticals management contacts

Related company profiles:

Founded in 1998, Gan & Lee Pharmaceuticals has successfully developed the first Chinese domestic insulin analog. The company has become one of the main suppliers of insulin in China and now strives to broaden its global coverage in the field of diabetes diagnosis and treatment. Headquartered in the Tongzhou Economic Development Area, Beijing, China, Gan & Lee has state-of-the-art buildings and GMP facilities. In 2014, it established a US subsidiary in New Jersey, and in 2019, Gan & Lee selected Linyi City, Shandong, China, to become its second domestic drug production site, with further plans to expand to North America, Europe, and other regions. Gan & Lee is committed to providing solutions to patients across the globe and providing a positive impact on patient lives. Our clinical development program is investigating new chemical entities and biologics to treat cardiovascular disease, metabolic disease, cancer and diseases in other therapeutic areas.

Company Details

Employees
490
Founded
-
Address
No.8 Nanfeng West 1st Street, Huoxian, Tongzhou District,beijing 101109,china
Phone
1-105-696-5000
Email
in****@****lee.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Website
ganlee.com
Keywords
Diabetes, Insulin, Biosimilars, Medical Device.
HQ
Tongzhou District, Beijing
Competitors
Getz Pharma, BeiGene, BaseCure Therapeutics Inc., Sanofi, Innovent Biologics, Zai Lab, Structure Therapeutics, Moderna, Biomm, Cornerstone Pharmaceuticals.
Looking for a particular Gan & Lee Pharmaceuticals employee's phone or email?

Gan & Lee Pharmaceuticals Questions

News

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial) - Yahoo Finance

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial) Yahoo Finance

A comparative evaluation of bioequivalence of Gan & Lee glargine U300 and Toujeo - Frontiers

A comparative evaluation of bioequivalence of Gan & Lee glargine U300 and Toujeo Frontiers

Gan & Lee touts 17.29% weight loss with GLP-1 agonist in Phase IIb trial - Clinical Trials Arena

Gan & Lee touts 17.29% weight loss with GLP-1 agonist in Phase IIb trial Clinical Trials Arena

Gan & Lee Pharmaceuticals' Three Innovative Drugs: GZR18 Injection, GZR4 Injection, and GZR101 Injection Achieve Primary Endpoints in Phase 2 Clinical Studies - PR Newswire

Gan & Lee Pharmaceuticals' Three Innovative Drugs: GZR18 Injection, GZR4 Injection, and GZR101 Injection Achieve Primary Endpoints in Phase 2 Clinical Studies PR Newswire

Gan & Lee Pharmaceuticals Announces Significant Progress on New Diabetes and Obesity Treatments at the American Diabetes Association's 84th Scientific Sessions - 팜뉴스

Gan & Lee Pharmaceuticals Announces Significant Progress on New Diabetes and Obesity Treatments at the American Diabetes Association's 84th Scientific Sessions 팜뉴스

Insulin Glargine Market Size, Share, And Opportunities to 2033 Ganlee, Sanofi-Aventis, Biocon - openPR.com

Insulin Glargine Market Size, Share, And Opportunities to 2033 Ganlee, Sanofi-Aventis, Biocon openPR.com

Investigational cyclin-dependent kinase 4/6 inhibitor GLR2007 demonstrates activity against isocitrate dehydrogenase wild-type glioblastoma and other solid tumors in mice xenograft models - Frontiers

Investigational cyclin-dependent kinase 4/6 inhibitor GLR2007 demonstrates activity against isocitrate dehydrogenase wild-type glioblastoma and other solid tumors in mice xenograft models Frontiers

Gan & Lee Pharmaceuticals' Bi-weekly (twice a month) GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical Trial - PR Newswire

Gan & Lee Pharmaceuticals' Bi-weekly (twice a month) GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical Trial PR Newswire

KEY STAT | Three of Hillhouse Capital’s healthcare investments went public on Monday - KrASIA

KEY STAT | Three of Hillhouse Capital’s healthcare investments went public on Monday KrASIA

Companies like Gan & Lee Pharmaceuticals

Cornerstone Pharmaceuticals logo - Similar company to Gan & Lee Pharmaceuticals

Cornerstone Pharmace...

20
BeiGene logo - Similar company to Gan & Lee Pharmaceuticals

Beigene

2.93K
Sanofi logo - Similar company to Gan & Lee Pharmaceuticals

Sanofi

88.33K
Biomm logo - Similar company to Gan & Lee Pharmaceuticals

Biomm

241
Innovent Biologics logo - Similar company to Gan & Lee Pharmaceuticals

Innovent Biologics

832
Moderna logo - Similar company to Gan & Lee Pharmaceuticals

Moderna

6.75K
BaseCure Therapeutics Inc. logo - Similar company to Gan & Lee Pharmaceuticals

Basecure Therapeutic...

6
Zai Lab logo - Similar company to Gan & Lee Pharmaceuticals

Zai Lab

533
Structure Therapeutics logo - Similar company to Gan & Lee Pharmaceuticals

Structure Therapeutics

175
Getz Pharma logo - Similar company to Gan & Lee Pharmaceuticals

Getz Pharma

5.81K

Top Gan & Lee Pharmaceuticals Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant